Monika Kutyna
0000-0003-2315-091X
12 papers found
Refreshing results…
A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World Data
Case report: Rare case of donor cell‐derived T‐cell acute lymphoblastic leukaemia in a female patient after receiving an allo‐transplant from her male sibling
TP53mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines
Seronegative Rheumatoid Arthritis and Innate Immune Activation is Frequent in Myeloid Neoplasms with Isocitrate Dehydrogenase 1/2 Mutations
Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability
A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure
Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer
The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution
Red cell autoimmunization and alloimmunization in myelodysplastic syndromes: prevalence, characteristic and significance
Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome
Dynamic assessment of RBC‐transfusion dependency improves the prognostic value of the revised‐IPSS in MDS patients
Missing publications? Search for publications with a matching author name.